STA-4783 + carboplatin + paclitaxel

STA-4783 (elesclomol) combined with carboplatin and paclitaxel is an investigational multi-agent chemotherapy regimen. Elesclomol is a small-molecule drug that induces oxidative stress in cancer cells by increasing reactive oxygen species, leading to apoptosis. It requires a redox-active metal ion for activity and has shown synergy with chemotherapeutic agents in preclinical models[1][2][3]. Paclitaxel is a microtubule stabilizer that inhibits cell division, while carboplatin is a platinum-based DNA crosslinker causing apoptosis. The combination aims to enhance antitumor efficacy through complementary mechanisms of action. This regimen has been studied in various solid tumors including melanoma, ovarian cancer, and soft tissue sarcoma[2][5][6].

Other names

elesclomol + carboplatin + paclitaxelCARBOPLATIN-TAXOL